{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:32:17Z","timestamp":1790764337646,"version":"4.1.0"},"reference-count":136,"publisher":"Informa UK Limited","issue":"2","funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders","doi-asserted-by":"crossref","award":["5PN2EY016525 (SG Potkin)"],"award-info":[{"award-number":["5PN2EY016525 (SG Potkin)"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders","doi-asserted-by":"crossref","award":["5U24RR021992 (SG Potkin)"],"award-info":[{"award-number":["5U24RR021992 (SG Potkin)"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Neurol."],"published-print":{"date-parts":[[2018,2,5]]},"DOI":"10.2217\/fnl-2017-0035","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T10:41:04Z","timestamp":1527590464000},"page":"101-121","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":31,"title":["New Directions in Therapeutics for Huntington Disease"],"prefix":"10.1080","volume":"13","author":[{"given":"Katya T","family":"Potkin","sequence":"first","affiliation":[{"name":"Stony Brook School of Medicine, 101 Nicolls Rd, Stony Brook, NY11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G","family":"Potkin","sequence":"additional","affiliation":[{"name":"Professor Emeritus, Department of Psychiatry & Human Behavior, University of California, Irvine, CA92697, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000116"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.24"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0501507102"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-007-9463-1"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7700-0"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2014.03.002"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24495"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2014.11.022"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8655"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1396-07.2007"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000198586.85250.13"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.09.053"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2006.08.035"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-0579-5_14"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4262-04.2005"},{"issue":"1","key":"e_1_3_4_17_1","first-page":"55","article-title":"Amantadine: a review of use in child and adolescent psychiatry","volume":"22","author":"Hosenbocus S","year":"2013","unstructured":"Hosenbocus S , ChahalR. Amantadine: a review of use in child and adolescent psychiatry. J. Can. Acad. Child Adolesc. Psychiatry22(1), 55\u201360 (2013).","journal-title":"J. Can. Acad. Child Adolesc. Psychiatry"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000068165.07883.64"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.1000"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.3.397"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.07.023"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70233-2"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25362"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12512"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70262-5"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00019.2013"},{"key":"e_1_3_4_28_1","unstructured":"Raptor Pharmaceuticals\n          . 18month clinical results showed significantly slower progression of total motor score in RP103 treated patients without tetrabenazine (2014). www.prnewswire.com\/news-releases\/raptor-plans-to-advance-rp103-in-a-registration-study-in-huntingtons-disease-based-on-favorable-treatment-effects-at-36-months-in-cyst-hd-trial-300191131.html."},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2012.05.009"},{"key":"e_1_3_4_30_1","unstructured":"Achey M\n          . Meet the compounds: WVE-120101 and WVE-120102 (2016). http:\/\/huntingtonstudygroup.org\/hd-insights\/meet-the-compounds-wve-120101-and-wve-120102\/."},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2008.01.032"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001214"},{"issue":"12","key":"e_1_3_4_33_1","first-page":"1582","article-title":"Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study","volume":"65","author":"Huntington Study Group TREND-HD Investigators.","year":"2008","unstructured":"Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch. Neurol.65(12), 1582\u20131589 (2008).","journal-title":"Arch. Neurol."},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26308"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/392169"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.162362299"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2015.01.002"},{"key":"e_1_3_4_38_1","article-title":"SIGNAL: a new investigational approach to early treatment of Huntington's disease","author":"Huntington Study Group","year":"2015","unstructured":"Huntington Study Group . SIGNAL: a new investigational approach to early treatment of Huntington's disease. Curr. HSG Res. Trials Stud. (2015). http:\/\/huntingtonstudygroup.org\/wp-content\/uploads\/2015\/06\/Signal-Flyer.pdf.","journal-title":"Curr. HSG Res. Trials Stud."},{"key":"e_1_3_4_39_1","article-title":"Treatment with VX15 may protect brain in early phase Huntington's, data shows","author":"Fernandes J","year":"2017","unstructured":"Fernandes J . Treatment with VX15 may protect brain in early phase Huntington's, data shows. Huntington's Disease News (2017). https:\/\/huntingtonsdiseasenews.com\/2017\/04\/27\/vx15-protect-brain-early-phase-huntingtons\/.","journal-title":"Huntington's Disease News"},{"key":"e_1_3_4_40_1","unstructured":"Vaccinex I\n          . Vaccinex Inc. Announces preliminary data from the SIGNAL clinical trial (investigational drug VX15\/2503 as a potential treatment for Huntington's disease) (2017). www.vaccinex.com\/vaccinex-inc-announces-preliminary-data-from-signal-clinical-trial\/."},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2007.00018.x"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2003.t01-1-01868.x"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2016.06.008"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep31652"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddl210"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004209"},{"key":"e_1_3_4_47_1","unstructured":"Annoucement of 2CARE Early Study Closure (2014). http:\/\/hdsa.org\/wp-content\/uploads\/2015\/01\/Announcement-of-2CARE-Early-Study-Closure.pdf."},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21181"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26174"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamaneurol.382"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2006.09.026"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4011"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2008.02.010"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0202-143"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01301"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm985"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0707842104"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.03.035"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1362"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddl017"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087513"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.1.85"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1222663110"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2006.04686.x"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0437870100"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M410210200"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804249105"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0606373103"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4286-09.2009"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8145-9"},{"key":"e_1_3_4_72_1","unstructured":"Voyager Therapeutics selects lead clinical candidate for Huntington's disease (2017). http:\/\/ir.voyagertherapeutics.com\/phoenix.zhtml?c=254026&p=irol-newsArticle&ID=2277966."},{"key":"e_1_3_4_73_1","unstructured":"uniQure's has demonstrated preclinical proof-of-concept and initiated IND-enabling studies in Huntington's disease (2017). www.uniqure.com\/gene-therapy\/huntingtons-disease.php."},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq464"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-159003"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M708192200"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-9525(01)02625-7"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2009.04.001"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddg169"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0857-08.2008"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1386"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-160191"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddw212"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/dds397"},{"issue":"8","key":"e_1_3_4_85_1","first-page":"1353","article-title":"Clinical experience with risperidone and memantine in the treatment of Huntington's disease","volume":"98","author":"Cankurtaran ES","year":"2006","unstructured":"Cankurtaran ES , OzalpE, SoygurH, CakirA. Clinical experience with risperidone and memantine in the treatment of Huntington's disease. J. Natl Med. Assoc.98(8), 1353\u20131355 (2006).","journal-title":"J. Natl Med. Assoc."},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.23.2.jnp206"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2056"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2010.01.008"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2013.11.013"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.5.694"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.7.996"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(01)02326-6"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622970701332520"},{"key":"e_1_3_4_94_1","article-title":"Lamotrigine","author":"Liou S","year":"2010","unstructured":"Liou S . Lamotrigine. Huntington's Outreach Project for Education, at Stanford (2010). http:\/\/web.stanford.edu\/group\/hopes\/cgi-bin\/hopes_test\/lamotrigine\/#research-on-lamotrigine.","journal-title":"Huntington's Outreach Project for Education, at Stanford"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1997.6520"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/189307"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1103-3"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022966"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-5-18"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.3916"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.20663"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S65738"},{"key":"e_1_3_4_103_1","unstructured":"TEVA Pharmaceutical Industries Ltd\n          . Teva announces results from exploratory 52-week Phase 2 PRIDE-HD study of pridopidine in Huntington disease (2016). www.tevapharm.com\/news\/teva_announces_results_from_exploratory_52_week_phase_2_pride_hd_study_of_pridopidine_in_huntington_disease_09_16.aspx."},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509345903"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.15.9158"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.04.026"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/77528"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000049936.85487.7A"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200411000-00004"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23236"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3600"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-120029"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2009.05843.x"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-0186(01)00060-2"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2006.09.015"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M609532200"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddm294"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1119472109"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2005.07.021"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.11.2828"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000194318.74946.b6"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.334"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddm064"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.128"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.9898"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21632"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-150183"},{"key":"e_1_3_4_129_1","unstructured":"Ionis Pharmaceuticals\n          . Dose-dependent reduction of mutant Huntingtin protein observed. Ionis earns $45 million license fee (2017). http:\/\/ir.ionispharma.com\/news-releases\/news-release-details\/ionis-pharmaceuticals-licenses-ionis-htt-rx-partner-following."},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04975.x"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107434"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.04.007"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70381-7"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03310-9"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24174"},{"issue":"11","key":"e_1_3_4_136_1","first-page":"1382","article-title":"Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease","volume":"70","author":"Marder K","year":"2013","unstructured":"Marder K , GuY, EberlySet al. Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. JAMA Neurol.70(11), 1382\u20131388 (2013).","journal-title":"JAMA Neurol."},{"key":"e_1_3_4_137_1","unstructured":"Tetrabenazine package insert. Sun Pharmaceutical Industries Limited Cranbury USA; February (2015). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206129Orig1s000lbl.pdf."}],"container-title":["Future Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fnl-2017-0035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:54Z","timestamp":1719125034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fnl-2017-0035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,5]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2,5]]}},"alternative-id":["10.2217\/fnl-2017-0035"],"URL":"https:\/\/doi.org\/10.2217\/fnl-2017-0035","relation":{},"ISSN":["1479-6708","1748-6971"],"issn-type":[{"value":"1479-6708","type":"print"},{"value":"1748-6971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifnl20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifnl20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}